Abstract
Background. Characterising disparities in HIV infection across populations by gender, age, and HIV risk is key information to guide intervention priorities. We compared 9 models representing 15 different settings across Africa to assess how indicators measuring HIV acquisitions, transmissions, or potential long-term infections influence estimates of the contribution of different populations to new infections, including key populations (KPs, including female sex workers (FSW), their clients, men who have sex with men). Methods. We evaluated four indicators: I1) acquisition indicator measuring the annual fraction of all new infections acquired by a specific population, I2) direct transmission indicator measuring the annual fraction of all new infections directly transmitted by a specific population, I3) 1-year and I4) 10-year transmission population-attributable fractions (tPAFs). tPAFs measure the fraction of new infections averted if transmission involving a specific population was blocked over a specific time period. We compared estimates of the four indicators across 7 populations and 15 settings and assessed if the contribution of specific populations is ranked differently across indicators for 10 settings. Findings. Indicators identified distinct priority populations as the largest contributors: The acquisition indicator (I1) identified women aged 25+ years outside KPs as contributing the most to acquired infections in 8/10 settings in 2020, but to direct transmissions (I2) in only two settings. In 6/10 settings, the 10-year tPAFs (I4) identified non-KP men aged 25+ years and clients of FSW as the largest contributors to HIV transmission. Notably, non-KP women aged 15-24 years acquired (I1) more infections in 2020 (median of 1.7-fold across models) than they directly transmitted (I2), while non-KP men aged 25+ years and clients of FSWs transmitted more infections than they acquired in all but one model (median: 1.4 and 1.6-fold, respectively). Estimates of the 10-year tPAFs accounting for transmission in the long-term were substantially larger than the direct transmission indicator for all populations, especially for FSW (median: 2.0-fold). Interpretation. Indicators that reflect HIV acquisitions and transmissions over the short and long term can be utilised to capture the complexity of HIV epidemics across different populations and timeframes. The added nuance would improve the effectiveness of the HIV prevention response across all populations at risk. Funding. NIH, MRC.
Competing Interest Statement
JWI-E reports research grants from the Gates Foundation, the US National Institutes of Health, UNAIDS, and UK Research and Innovation; personal fees from BAO Systems; and support for meeting travel from UNAIDS, the International AIDS Society, and the Gates Foundation, all outside the submitted work. MCB reports research funding for unrelated projects from the Wellcome Trust and CIHR. RSt reports unrelated contracts with the Gates Foundation. The remaining authors have no conflicts of interest to disclose.
Funding Statement
Supported partly by UNAIDS and the HPTN Modelling Centre, which is funded by the U.S. National Institutes of Health (NIH UM1 AI068617) through HPTN. RSi, RDB, KMM, JSta, OS, JWI-E and M-CB acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global health EDCTP3 Joint Undertaking. RSi, JSton, PV, M-CB and MM-G acknowledge funding from the Wellcome Trust (WT 226619/Z/22/Z). MM-G and SM's research program are supported by Tier 2 Canada Research Chairs in Population Health Modeling and Mathematical Modeling and Program Science, respectively. AB was supported by the US National Institutes of Health (NIH R01AI179417). Support for EMOD-HIV and Thembisa was provided by the Gates Foundation. Country models utilized for Optima HIV have been supported by the Gates Foundation, Global Fund, and the World Bank.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos